Tandem Diabetes Care, Inc. (TNDM - Free Report) is slated to report third-quarter 2019 results on Nov 4, after market close. In the last reported quarter, the company delivered a positive earnings surprise of 86.9%. Tandem Diabetes’ earnings beat the Zacks Consensus Estimate in the last four quarters, the average being 60.9%.
Let's take a look at how things are shaping up prior to this announcement.
Tandem Diabetes' strong earnings growth trajectory is expected to have continued in the third quarter, courtesy of a strong global surge in sales of its t:slim X2 insulin pump. Particularly, the pump has been registering strong momentum within the Animas customer segment.
The positive customer reception for the pump and the Tandem Device Updater are expected to have driven growth for the company during the third quarter.
Solid adoption of the recently-launched Basal-IQ technology among healthcare providers is also expected to have contributed to the company’s top line during the quarter.
Internationally, over the recent past, majority of the company’s sales have been driven by an increasing number of Animas conversions. We expect this trend to have continued through the to-be-reported quarter.
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is exactly the case here as you will see below.
Earnings ESP: Tandem Diabetes has an Earnings ESP of +33.33%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:Tandem Diabetes carries a Zacks Rank #2.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season.
Patterson Companies (PDCO - Free Report) has an Earnings ESP of +2.44% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
AmerisourceBergen Company (ABC - Free Report) has an Earnings ESP of +0.55% and a Zacks Rank #3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +0.69% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>